RXi Pharmaceuticals, the Worcester, MA-based developer of RNA interference drugs, said today it has obtained an exclusive worldwide license to RNAi delivery technologies from Advirna. The technology is supposed to make it easier to deliver RNAi without liposomes, nanoparticles, or other methods that add complexity, RXi said (NASDAQ: [[ticker:RXII]]). Terms of the deal weren’t disclosed.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
